From: Surveillance for early stages of colon cancer: potentials for optimizing follow-up protocols
 | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
 | DFS HR (95 % CI) | OS HR (95 % CI) | DFS HR (95 % CI) | OS HR (95 % CI) |
Gender | ||||
Female | 1 | 1 | 1 | 1 |
Male | 0.59 (0.25–1.40) | 0.57 (0.21–1.57) | 0.41 (0.16–1.05) | 0.41 (0.14–1.25) |
Age, years | 1.06 (1.01–1.12) | 1.09 (1.02–1.16) | 1.07 (1.01–1.12) | 1.09 (1.02–1.16) |
Budding | ||||
 No | 1 | 1 | 1 | 1 |
 Yes | 1.72 (0.67–4.44) | 1.09 (0.31–3.85) | 1.22 (0.35–4.16) | 1.06 (0.23–4.87) |
Fibrosis | ||||
 <50 % | 1 | 1 | 1 | 1 |
 > = 50 % | 1.98 (0.77–5.10) | 1.23 (0.35–4.35) | 1.21 (0.37–3.94) | 1.01 (0.22–4.61) |
Stage | ||||
 1 | 1 | 1 | 1 | 1 |
 2A | 1.11 (0.42–2.93) | 0.80 (0.26–2.46) | 1.08 (0.35–3.30) | 1.13 (0.31–4.13) |
 2B | 2.89 (0.58–14.35) | 3.68 (0.71–19.00) | 4.07 (0.63–26.08) | 5.81 (0.77–43.92) |
Lymph nodes retrieved | ||||
 > = 12 | 1 | 1 | 1 | 1 |
 <12 | 2.56 (1.09–6.25) | 2.70 (1.03–7.69) | 2.13 (0.76–5.88) | 2.38 (0.71–8.33) |
Vascular invasion | ||||
 No | 1 | 1 | 1 | 1 |
 Yes | 3.78 (1.12–12.91) | 3.19 (0.72–14.15) | 3.43 (0.87–13.58) | 2.91 (0.59–14.31) |
Lymphatic invasion | ||||
 No | 1 | 1 | 1 | 1 |
 Yes | 1.71 (0.63–4.67) | 0.83 (0.19–3.69) | 0.88 (0.26–2.94) | 0.85 (0.09–2.89) |
Site | ||||
 Right or trasversum | 1 | 1 | 1 | 1 |
 Left or double | 2.69 (1.04–6.93) | 2.06 (0.70–6.04) | 3.56 (1.24–10.21) | 3.34 (0.98–11.84) |
Chemotherapy | ||||
 No | 1 | 1 | 1 | 1 |
 Yes | 1.12 (0.38–3.34) | 0.76 (0.17–3.37) | 1.52 (0.39–5.97) | 1.37 0.24–7.99) |